Clarigent Health, a mental health technology company, launched Clairity, an app-based listening tool designed to provide clinical decision making support to mental health professionals. Clairity is able to analyse speech patterns and behaviours through AI, to objectively identify patients who may be at risk of committing suicide.
Clairity AI identifies vocal biomarkers – noninvasive, objective indicators of mental health states. The vocal biomarkers are tracked over time alongside patient-reported symptoms. Voice and clinical data are captured by the Clairity app, or can be imported securely if they have been recorded elsewhere. Clairity analyses the results and then provides personalized session summaries, patient-specific treatment progress, and aggregated data to help assess risk across a patient group.
The launch of Clairity comes during a time in which clinicians are facing surmounting levels of mental health crises linked to months of anxiety and isolation brought upon by the COVID-19 pandemic. The continued need for social distancing has led to a rise in telehealth sessions, which has brought about new concerns for mental health professionals, who often rely on in-person interactions to identify signals of mental health concerns. This is where Clairity will come in. The Clairity product suite is compatible with telehealth platforms and can also be used for support in regular in-person consultations as well.
“We want to help save lives and prevent anyone from falling through the cracks,” said Clarigent founder and CEO, Don Wright. “Clairity provides the right data to the clinician at the right time to support them in making the right care decisions. Clinicians can also share this with their patients, providing views of treatment progress. We believe Clairity can be a catalyst for a shared decision-making care model.”
Established in 2018, Clarigent Health creates HIPAA-compliant solutions built upon AI algorithms and research and data, including recordings of children and adults undergoing treatment at multiple clinical sites. The foundational science comes from research at Cincinnati Children’s Hospital Medical Center led by Dr. John Pestian and Dr. Tracy Glauser.